Quick answer: latest quarter results, by ticker or company name

Reported Q: Q1 2025 Rev YoY: -52.5% EPS YoY: +62.8% Move: -3.86%

VistaGen Therapeutics Inc

VTGN

$0.547 -3.86%

Exchange NASDAQ Sector Healthcare Industry Biotechnology

Q1 2025

Published: Aug 13, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for VTGN

Reported

Report Date

Aug 13, 2024

Quarter Q1 2025

Revenue

84.00K

YoY: -52.5%

EPS

-0.35

YoY: +62.8%

Market Move

-3.86%

Previous quarter: Q4 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $0.08M down 52.5% year-over-year
EPS of $-0.35 increased by 62.8% from previous year
Gross margin of 100.0%
Net income of -10.73M
""What drives our team day in and day out is the opportunity to improve patient lives with our pioneering neuroscience." - Shawn Singh, CEO" - Shawn Singh

VTGN

VistaGen Therapeutics Inc

Period Q1 2025

Currency USD

Report Type Quarterly Earnings

Generated Mar 30, 2026

Swipe to view all report sections

Executive Summary

VistaGen Therapeutics Inc (VTGN) reported its fiscal year 2025 first-quarter results, showcasing a revenue of $84,000, a significant decrease of 52.54% year-over-year and a 57.43% decline from the previous quarter. Net loss widened to $10.7 million compared to $6.9 million in the same quarter last year. R&D expenses rose to $7.6 million due to increased clinical trials, particularly for the Phase 3 PALISADE programs targeting social anxiety disorder (SAD). Management remains confident in its pipeline, specifically regarding the registration-directed PALISADE-3 trial for Fasedienol, which could establish the first FDA-approved acute treatment for SAD.

Key Performance Indicators

Revenue

Decreasing

84.00K

QoQ: -57.43% | YoY: -52.54%

Gross Profit

Decreasing

84.00K

1.00% margin

QoQ: -57.43% | YoY: -52.54%

Operating Income

Decreasing

-12.13M

QoQ: -6.80% | YoY: -73.35%

Net Income

Decreasing

-10.73M

QoQ: -12.73% | YoY: -55.48%

EPS

Increasing

-0.35

QoQ: 0.00% | YoY: 62.77%

Revenue Trend

Margin Analysis

Financial Highlights

Financial Metrics:
- Revenue: $84,000, down 52.54% YoY, down 57.43% QoQ
- R&D Expenses: $7.6 million, up from $4.2 million YoY
- General and Administrative Expenses: $4.6 million, up from $3 million YoY
- Net Income: -$10.7 million, worsening from -$6.9 million YoY
- Cash Position: $108.4 million in cash and marketable securities
- EPS: -$0.35.
The increase in R&D expenditure is attributed to ongoing PALISADE-3 clinical trials and preparation for further studies, which is positive for long-term growth despite current financial losses.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	84.00K	-52.54%	-57.43%
Gross Profit	84.00K	-52.54%	-57.43%
Operating Income	-12.13M	-73.35%	-6.80%
Net Income	-10.73M	-55.48%	-12.73%
EPS	-0.35	62.77%	0.00%

Key Financial Ratios

Gross Profit Margin

Weak

1.00%

Gross profit margin is below industry norms, profitability concerns

Operating Profit Margin

Weak

-144.42%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-127.77%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.09%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.10%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

17.77

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.02

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-2.54x

Negative earnings make P/E ratio not meaningful

Price to Book

Fair Value

1.04x

Price-to-book ratio reasonable for profitable companies

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q1 2026	0.24	-0.47	+23.7%	View
Q3 2025	0.23	-0.46	-43.1%	View
Q2 2025	0.18	-0.42	-34.2%	View
Q1 2025	0.08	-0.35	-52.5%	View
Q4 2024	0.20	-0.35	+12.4%	View

VTGN

VistaGen Therapeutics Inc

Q1 2026 Report

VistaGen Therapeutics Inc (VTGN) QQ1 2026 Earnings Analysis: PALISADE Phase III Progress, Open-Label Safety Signals, and Near-Term Catalysts...

Read full report

VTGN

VistaGen Therapeutics Inc

Q3 2025 Report

VistaGen Therapeutics Inc (VTGN) Q3 2025 Financial Results: Navigating Clinical Advancements and Financial Challenges...

Read full report

VTGN

VistaGen Therapeutics Inc

Q2 2025 Report

VistaGen Therapeutics Inc (VTGN) QQ2 2025 Financial Results Report: Navigating Through Growth Challenges...

Read full report

VTGN

VistaGen Therapeutics Inc

Q4 2024 Report

VistaGen Therapeutics Inc (VTGN) Q4 2024 Financial Results: Strategic Milestones and Challenges in CNS Therapeutics...

Read full report

VistaGen Therapeutics Inc (VTGN) Q1 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Historical Earnings Comparison

More VTGN Quarterly Reports

VTGN

VTGN

VTGN

VTGN

Q1 2025 Reports in Healthcare Sector

ALZN

Related Financial Data

Sector Analysis: Healthcare

VTGN Full Profile

VTGN Financial Statements

Earnings Calendar